Close Menu

NEW YORK (360Dx) – The US Food and Drug Administration has given de novo clearance of Baebies' Seeker platform for quantitatively measuring the activity of lysosomal enzymes α-L-iduronidase, α-D-glucosidase, β-glucocerebrosidase, and α-D-galactosidase A from newborn dried blood spot specimens, the company said recently.

Reduced activity of these enzymes may suggest lysosomal storage diseases (LSD) mucopolysaccharidosis type 1, Pompe, Gaucher, or Fabry, Baebies said. It added that Seeker is the only FDA-authorized test on the market for LSDs.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.